AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Population Pharmacokinetics of HIV-specific Broadly Monoclonal Neutralizing Long-acting Antibody, VRC01LS, in Term InfantsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Time Course of Tenofovir-Diphosphate Carryover in DBS Following TDF to TAF SwitchView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Plasma and Breastmilk Pharmacokinectics of Tenofovir Using Dried Blood and Breast Milk Spots in HIV Infected Postpartum Women in UgandaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Steady-State Plasma Tfv/FTC Among Adolescent Transgender Men and Women Receiving Directly Observed Daily Tdf/FtcView Abstract
PosterHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Evaluation of Relationships Between AB-506 Related ALT Elevations and AB-506 Pharmacokinetics (PK), Metabolite Concentrations and Plasma Bile AcidsView Poster
PosterHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Systematic Review and Meta-Analysis of Adverse Perinatal Outcomes Associated With Prenatal Exposure to Protease Inhibitor Combination in Pregnant Women With HIV InfectionView Poster
PosterHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Impact of the Hepatitis B Virus (HBV) Capsid Inhibitor, AB-506, on the Single Dose Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)View Poster
PosterHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020In Utero Exposure to Antiretroviral Drugs and Pregnancy Outcomes: A Secondary Analysis of the ANRS Pharmacovigilance Database From the ANRS-Sponsored HIV Research StudiesView Poster
PosterHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Pharmacokinetics, Safety, and Tolerability of Dolutegravir + Rilpivirine (JULUCA) in Healthy Japanese AdultsView Poster
PosterHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020The Pharmacokinetics (PK) of DOVATO (50 mg Dolutegravir (DTG)/ 300 mg Lamivudine (3TC)) Fixed-Dose Combination in HIV-Infected PatientsView Poster
PosterHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Tacrolimus and Sirolimus Doses in an HIV-Infected, Kidney-Recipient, Patient Requiring a Cobicistat-Based Antiretroviral RegimenView Poster
PosterHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Population Pharmacokinetic Modelling of Atazanavir in Plasma and Hair of HIV-Infected WomenView Poster
